Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ARCHIVE
ARCHIVE
- Call For “Copayment Revision”Remains Unchanged in Revised SS Reform Plan
June 27, 2011
- NCC, Shimadzu Tie Up to Develop Advanced Cancer Treatment Technology
June 27, 2011
- Takeda Sues 18 Generic Companies for Actos Patent Infringement
June 27, 2011
- Compassionate Use of Unapproved Drugs to Require Clarification of Roles, Responsibilities
June 27, 2011
- Sangi Develops Oral Formulation for Cisplatin
June 27, 2011
- Taiyo's Acquisition by Teva Provides New Opportunity for GE Ind.: Mr Honda of Mylan
June 27, 2011
- FDA Issues Warning on Bladder Cancer Risk Associated with Actos
June 27, 2011
- Pfizer to Conduct First-ever “Virtual Clinical Trial”
June 27, 2011
- Do Practice and Experience Maketh the Marketer?
June 27, 2011
- Korosho to Promptly Assess Bladder Cancer Risk due to Actos
June 27, 2011
- Dacogen Increases OS in AML Patients: Eisai
June 27, 2011
- Aratani Family Excluded from Teva-Controlled Taiyo
June 27, 2011
- Novartis, Ono to Promote Rivastigmine Stressing Its Beneficial Effects on ADL
June 27, 2011
- All Clinical Studies Need to Be Conducted According to Global Standards: Expert Committee
June 27, 2011
- Lenvatinib Shows ORR of 59% in Global PII: Eisai
June 27, 2011
- Merck to License Biosimilar of Enbrel from Hanwha of South Korea
June 27, 2011
- Daiichi Sankyo Confident about Independently Expanding Share for Memary
June 27, 2011
- Korosho to Enhance Generics' Reliability: Minister Hosokawa
June 27, 2011
- PIII Study Confirms Safety, Efficacy of Rotigotine Patch: Otsuka
June 27, 2011
- Mr Yoshida Points Out Need to Review NHI Pricing Rules for Generics
June 27, 2011
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…